In cooperation with University of California Irvine, Essentialis Therapeutics conducted a Phase 1 clinical trial testing the impact of diazoxide choline on hyperphagia, resting energy expenditure, and weight in individuals with PWS. This was a single-center, open-label, single-arm study with a double-blind, placebo-controlled, randomized withdrawal extension.
Trial results were reported here.
For more details on study specifics, please visit the clinicaltrials page here.
FPWR is honored to have provided funding to partially support this clinical study.